MDR Impact on Pharma Companies

14:00 - 14:35

With the introduction of new EU MDR pharma companies must ensure readiness for the implementation in May 2020. However, specifically for single integral medical products with a device component there is still many unknowns. This talk will include an industry perspective as well as case studies of how MDR Art 117 readiness can be approached in this time of uncertainty.

Bjorg K. Hunter, Regulatory Manager, Devices, GSK